Literature DB >> 26309891

Tachyphylaxis during ranibizumab treatment of exudative age-related macular degeneration.

Sibel Doguizi1, Sengul Ozdek2, Selcen Yuksel3.   

Abstract

Entities:  

Year:  2015        PMID： 26309891      PMCID： PMC4539654          DOI： 10.3980/j.issn.2222-3959.2015.04.37

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN： 2222-3959            Impact factor:   1.779


× No keyword cloud information.
  12 in total

1.  Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?

Authors:  Susanne Binder
Journal:  Br J Ophthalmol       Date:  2012-01       Impact factor: 4.638

Review 2.  Epidemiology of major eye diseases leading to blindness in Europe: a literature review.

Authors:  Elena Prokofyeva; Eberhart Zrenner
Journal:  Ophthalmic Res       Date:  2011-11-26       Impact factor: 2.892

3.  Temporal pattern of resolution/recurrence of choroidal neovascularization during bevacizumab therapy for wet age-related macular degeneration.

Authors:  Haiyan Wang; Giulio Barteselli; William R Freeman; Su Na Lee; Jay Chhablani; Sharif El-Emam; Lingyun Cheng
Journal:  Int J Ophthalmol       Date:  2013-10-18       Impact factor: 1.779

4.  Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis.

Authors:  Farzin Forooghian; Emily Y Chew; Catherine B Meyerle; Catherine Cukras; Wai T Wong
Journal:  Acta Ophthalmol       Date:  2011-03       Impact factor: 3.761

5.  Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation.

Authors:  Julie L Gasperini; Amani A Fawzi; Ani Khondkaryan; Linda Lam; Lawrence P Chong; Dean Eliott; Alexander C Walsh; John Hwang; SriniVas R Sadda
Journal:  Br J Ophthalmol       Date:  2011-07-26       Impact factor: 4.638

6.  Impact of AREDS in a developing country 5 years after publication of the study.

Authors:  Daoud C Fahed; Nicola G Ghazi; Nabil M Jabbour; Charbel D Fahed; John C Fahed; Haytham I Salti
Journal:  Eur J Ophthalmol       Date:  2011 Jan-Feb       Impact factor: 2.597

7.  Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration.

Authors:  Farzin Forooghian; Catherine Cukras; Catherine B Meyerle; Emily Y Chew; Wai T Wong
Journal:  Retina       Date:  2009-06       Impact factor: 4.256

8.  Prevalence of age-related macular degeneration in the United States.

Authors:  David S Friedman; Benita J O'Colmain; Beatriz Muñoz; Sandra C Tomany; Cathy McCarty; Paulus T V M de Jong; Barbara Nemesure; Paul Mitchell; John Kempen
Journal:  Arch Ophthalmol       Date:  2004-04

9.  Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration.

Authors:  Pearse A Keane; Sandra Liakopoulos; Sharel C Ongchin; Florian M Heussen; Sandeep Msutta; Karen T Chang; Alexander C Walsh; Srinivas R Sadda
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04-11       Impact factor: 4.799

10.  Rationale for combination therapy in age-related macular degeneration.

Authors:  Richard F Spaide
Journal:  Retina       Date:  2009-06       Impact factor: 4.256
View more
  5 in total

1.  Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept.

Authors:  Chikako Hara; Taku Wakabayashi; Yoko Fukushima; Kaori Sayanagi; Ryo Kawasaki; Shigeru Sato; Hirokazu Sakaguchi; Kohji Nishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-09-03       Impact factor: 3.117

2.  Nonresponders to Ranibizumab Anti-VEGF Treatment Are Actually Short-term Responders: A Prospective Spectral-Domain OCT Study.

Authors:  Georgios Bontzos; Saghar Bagheri; Larissa Ioanidi; Ivana Kim; Ioannis Datseris; Evangelos Gragoudas; Stamatina Kabanarou; Joan Miller; Miltiadis Tsilimbaris; Demetrios G Vavvas
Journal:  Ophthalmol Retina       Date:  2019-11-11

3.  Response to Aflibercept Therapy in Three Types of Choroidal Neovascular Membrane in Neovascular Age-Related Macular Degeneration: Real-Life Evidence in the Czech Republic.

Authors:  Jan Nemcansky; Alexandr Stepanov; Michal Koubek; Miroslav Veith; Yun Min Klimesova; Jan Studnicka
Journal:  J Ophthalmol       Date:  2019-06-10       Impact factor: 1.909

4.  Asymmetric response to ranibizumab in mixed choroidal neovascularization in a neovascular age-related macular degeneration diagnosed on OCT angiography - case report.

Authors:  Martin Pencak; Miroslav Veith
Journal:  BMC Ophthalmol       Date:  2021-01-15       Impact factor: 2.209

5.  Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab.

Authors:  Flora Elwes; Shyamanga Borooah; Peter Aspinall; Peng Yong Sim; Cheng Yi Loo; Ana-Maria Armbrecht; Baljean Dhillon; Peter Cackett
Journal:  BMC Ophthalmol       Date:  2018-01-30       Impact factor: 2.209
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.